Avantor price target raised to $35 from $33 at Citi 06:32 AVTR Citi analyst Patrick Donnelly raised the firm's price target on Avantor to $35 from $33 and keeps a Buy rating on the shares following the company's Q4 results. While the quarter and the outlook were "de-risked" following the preannouncement, end-market strength is a positive sign for the forward trajectory and further reinforcement of the conservatism embedded in guidance, Donnelly tells investors in a research note. Ball reports Q4 EPS 68c, consensus 78c Ball sees FY21 EPS over growth goal of 10%-15% Stellantis initiated with an Overweight at Morgan Stanley 05:26 STLA Morgan Stanley analyst Harald Hendrikse initiated coverage of Stellantis with an Overweight rating and EUR 16 price target. The analyst views the shares as "very cheap" despite the late 2020 rally. With "strong" execution, Stellantis has opportunities for "substantial" synergies to lead the European battery electric vehicle transition and to develop new businesses, Hendrikse tells investors in a research note.
TY janes for your research & imput. I would like to make you HOPS! Head Of Plastic Soltions Congrats! You now work at gummybear advisors where a shoulder rub is just that and nothing more...... Synthesis Energy Systems discloses additional Nasdaq delinquency notice 02/21/20 SES Synthesis Energy Systems announced that the company received an additional staff determination delinquency notification letter from the The Nasdaq Stock Market LLC due to the company's non-compliance with Nasdaq Listing Rule 5250(c)(1), as a result of the company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2019. The company is required to present its views with respect to this additional deficiency to the Panel in writing no later than February 27, 2020 under Listing Rule 5810(d). Robert Rigdon, the company's CEO, commented: "The company is progressing its important merger transaction with AFE and acquisition of additional ownership in Batchfire Resources. We believe these transactions, now underway, have the potential to bring growth and value to the company's shareholders and debenture holders. The late filing of our Form 10-Q for the quarter ended December 31, 2019 is the result delays related to derivative accounting protocol and value analysis regarding the merger-related debt restructuring undertaken by the company in October 2019. We are actively working with our auditors and our advisors to complete the work in the most expeditious manner possible." Ranpak Holdings CEO: Sustainability is at the core of what we do 01/22 PACK In an interview on CNBC's Mad Money Omar Asali said Ranpak is 100% paper and fiber based, a leader in environmentally friendly packaging. It has equipment that customizes the size of the box so waste is limited, Asali added. 50% of the company's business in the U.S. "We provide services to all the big e-commerce players in the U.S.," he noted. Ranpak is investing in material science with a focus on building solutions in the cold chain. According to Asali, the company aims to replace styrofoam. janes thisis the one that caught my attention----- Avantium upgraded to Hold from Reduce at Kepler Cheuvreux 01/27 AVTXF Kepler Cheuvreux analyst Patrick Roquas upgraded Avantium to Hold from Reduce with a EUR 6.20 price target. 6.20 EUR = Currency Converter 6.2Euroequals $7.44United States Dollar stk is $7.00 Replacing the Meg- I also found One more for your list! Description good natured Products Inc., through its subsidiaries, designs, produces, and distributes bioplastics for use in packaging and durable product applications in Canada and the United States. It offers packaging products for baked goods, deli and prepared meals, and fruits and veggies; desk accessories, including stackable legal desk trays, vertical file holders, self-stacker desk trays, pencil holders, and paper clip dispensers; recyclers and waste bins; and totes and crates, as well as compostable take out containers, such as hot cups and lids, plates, carry out boxes, cutlery, and soup bowls and lids. The company was formerly known as Solegear Bioplastic Technologies Inc. and changed its name to good natured Products Inc. in October 2017. The company is headquartered in Vancouver, Canada. good natured Products Inc. (SLGBF) Other OTC - Other OTC Delayed Price. Currency in USD Add to watchlist 1.1427+0.1888 (+19.79%)<---------------- At close: February 3
1 Mo move on SLGBF 70 cents to--> $1.14 Atossa Therapeutics, Inc. (ATOS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD 3.2500+0.4500 (+16.07%)<--------CLODSE At close: February 3 4:00PM EST 4.3500+1.10 (33.85%)<----------OPEN-! +33% Before hours:8:10AM EST
One Medical Investor Presentation Gill's ONEM stock calls follow last week's JPMorgan Healthcare Conference at which she hosted presentations by One Medical CEO Amir Rubin, among others. Gill noted during the Jan. 12 presentation that a 60 Net Promoter Score, the net share of consumers likely to recommend a service, is good in health care. She called One Medical's 90 rating "off the charts." Rubin explained that One Medical's popularity comes from seamlessly coordinating care on behalf of members through digital channels. That includes reminders that it's time for a cancer screening, to scheduling appointments and sharing records with specialists at its local health network partners. One Medical's role is " to own that complexity on behalf of consumers," Rubin said. One Medical's role in Covid vaccinations will have an impact on revenue, but other effects of serving the community are more meaningful. Rubin noted that anyone can seek their vaccination through One Medical, not just members. "Coming out of that, consumers get exposure to One Medical," as do employers, Rubin said. He added that One Medical has been serving a number of schools and universities. In a discussion of telehealth, Rubin noted that One Medical has made its digital services available even in markets where it doesn't have clinics. The reason: The company is "now starting to engage with multimarket employers," Rubin said, expanding its market opportunity. On Jan. 8, Piper Sandler analyst Sean Wieland raised his ONEM stock price target to 51 from 44, citing his firm's proprietary app download analysis. Wieland noted 38,500 One Medical app downloads in Q4. That compares to One Medical's guidance of 19,000 to 29,000 new members in the quarter. ONEM Stock Analysis ONEM stock surged 12% to 47.71 in Tuesday's stock market action, breaking out from a 27-weekcup-with-handlebase, according to aMarketSmith analysis. Thebuy pointis 10 cents above the handle high of 44.49 on Jan. 4. The buy zone runs through 46.82, 5% above the buy point.--> Now $53
--Aemetis engages Koch Project for expansion projects AMTX --Tapestry sees increase in demand for key categories as vaccine rollout continues TPR
Array Technologies price target raised to $60 from $55 at Roth Capital FluroTech appoints Brian Shield to Advisory Board ยป 08:24 FLURF FluroTech announced
Atossa Therapeutics Inc NASDAQ: ATOS Pre-market 4.62 +1.37 (42.15%) Stoney, you're holding on to it, right? I'm super tempted to sell at this high, but last time I sold it it was a mistake.... Just went up to 4.8.